A Critical Assessment of Remdesivir

IF 0.3 Q4 PHARMACOLOGY & PHARMACY

Current Drug Therapy Pub Date : 2023-10-31 DOI:10.2174/0115748855255004231001182927

Subhash Chandra, Alka N Choudhary, Santwana Palai, Abdur Rauf, Hassan Y. Aboul-Enein

引用次数: 0

Abstract

Abstract: The COVID-19 pandemic that originated in Wuhan city, China, has affected every village in India. This has killed millions of people. This disease involves symptomatic and asymptomatic mutations. The purpose of this review was to assess the effectiveness of remdesivir particularly against SAR-CoV-2 (Coronaviridae family). The relevant works have been studied with respect to the drug's chemistry, mechanism of action, pharmacokinetics, pharmacodynamics, clinical data, and side effects. Remdesivir has been used in many cases of coronavirus-infected patients because it has been proven to possess beneficial effects; however, significant adverse effects have also been reported. Remdesivir has been reported to help in lowering the disease's high fatality rate. However, the WHO has warned against using the medicine because there is no clinical data to support its therapeutic efficacy.

查看原文本刊更多论文

对瑞德西韦的关键评价

摘要:新冠肺炎疫情发源于中国武汉市，影响到印度的每一个村庄。这已经造成数百万人死亡。这种疾病包括有症状和无症状的突变。本综述的目的是评估瑞德西韦的有效性，特别是对sars - cov -2(冠状病毒科)的有效性。对该药物的化学、作用机制、药代动力学、药效学、临床资料和副作用等方面进行了研究。瑞德西韦已被用于许多冠状病毒感染的患者，因为它已被证明具有有益的效果;然而，也有严重的不良反应的报道。据报道，雷姆德西韦有助于降低这种疾病的高致死率。然而，世界卫生组织警告不要使用这种药物，因为没有临床数据支持其治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Drug Therapy PHARMACOLOGY & PHARMACY-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.